Patient characteristics
| Characteristic . | No. of patients/total no. . | % . |
|---|---|---|
| Age, y | ||
| 60-64 | 12/59 | 20.3 |
| 65-69 | 26/59 | 44.1 |
| 70-75 | 20/59 | 33.9 |
| Older than 75 | 1/59 | 1.7 |
| Sex | ||
| Female | 24/59 | 40.7 |
| Male | 35/59 | 59.3 |
| Ann Arbor stage | ||
| IA | 1/59 | 1.7 |
| IB | 0 | 0 |
| IIA | 2/59 | 3.4 |
| IIB | 3/59 | 5.1 |
| IIIA | 16/59 | 27.1 |
| IIIB | 17/59 | 28.8 |
| IVA | 3/59 | 5.1 |
| IVB | 17/59 | 28.8 |
| Stage according to GHSG classification | ||
| Early favorable stages | 1/59 | 1.7 |
| Early unfavorable stages | 3/59 | 5.1 |
| Advanced stages | 55/59 | 93.2 |
| Histology | ||
| Mixed cellularity | 29/59 | 49.2 |
| Nodular sclerosis | 23/59 | 39.0 |
| Lymphocyte-rich classic HL | 3/59 | 5.1 |
| Classic HL, not specified | 3/59 | 5.1 |
| Lymphocyte predominant | 1/59 | 1.7 |
| International Prognostic Score* | ||
| 0-1 | 3/42 | 7.1 |
| 2-3 | 20/42 | 47.6 |
| 4-7 | 19/42 | 45.2 |
| Characteristic . | No. of patients/total no. . | % . |
|---|---|---|
| Age, y | ||
| 60-64 | 12/59 | 20.3 |
| 65-69 | 26/59 | 44.1 |
| 70-75 | 20/59 | 33.9 |
| Older than 75 | 1/59 | 1.7 |
| Sex | ||
| Female | 24/59 | 40.7 |
| Male | 35/59 | 59.3 |
| Ann Arbor stage | ||
| IA | 1/59 | 1.7 |
| IB | 0 | 0 |
| IIA | 2/59 | 3.4 |
| IIB | 3/59 | 5.1 |
| IIIA | 16/59 | 27.1 |
| IIIB | 17/59 | 28.8 |
| IVA | 3/59 | 5.1 |
| IVB | 17/59 | 28.8 |
| Stage according to GHSG classification | ||
| Early favorable stages | 1/59 | 1.7 |
| Early unfavorable stages | 3/59 | 5.1 |
| Advanced stages | 55/59 | 93.2 |
| Histology | ||
| Mixed cellularity | 29/59 | 49.2 |
| Nodular sclerosis | 23/59 | 39.0 |
| Lymphocyte-rich classic HL | 3/59 | 5.1 |
| Classic HL, not specified | 3/59 | 5.1 |
| Lymphocyte predominant | 1/59 | 1.7 |
| International Prognostic Score* | ||
| 0-1 | 3/42 | 7.1 |
| 2-3 | 20/42 | 47.6 |
| 4-7 | 19/42 | 45.2 |
Missing in 17 patients.